Section 1. Identification

1.1 Product identifier

Product name: Polyclonal Rabbit Antibody Solution

Part no.: A0001, A0002, A0008, A0011, A0012, A0021, A0022, A0024, A0030, A0031, A0033, A0040, A0061, A0062, A0063, A0065, A0072, A0077, A0080, A0082, A0092, A0093, A0094, A0098, A0099, A0100, A0101, A0115, A0118, A0133, A0136, A0137, A0146, A0186, A0190, A0191, A0192, A0193, A0194, A0206, A0224, A0225, A0230, A0231, A0245, A0251, A0253, A0262, A0257, A0296, A0301, A0302, A0370, A0373, A0384, A0398, A0408, A0423, A0424, A0425, A0426, A0451, A0452, A0485, A0562, A0564, A0566, A0568, A0569, A0570, A0576, A0623, A4502, A5109, A5110, A5113, A5114, A5115, B0114, B0357, B0471, B0586, Q0023, Q0102, Q0121, Q0122, Q0149, Q0326, Q0327, Q0328, Q0329, Q0330, Q0331, Q0332, Q0333, Q0362, Q0363, Q0367, Q0368, Q0369, Q0495, Q0496, Q0497, Q0498, Q0499, Q9127, OA016, OA026, OA044, OA500, OA521, OA522, OA529, OA541, OA854, OA855, OA87, X0903, X0936, Z5116

Validation date: 7/24/2019

1.2 Relevant identified uses of the substance or mixture and uses advised against

Material uses: Laboratory use

Container type: Bottle (50 ml to 3 L)

A0001 // Polyclonal Rabbit Anti-Human Albumin // 0.05 - 3 L
A0002 // Polyclonal Rabbit Anti-Human Prealbumin // 0.05 - 3 L
A0008 // Polyclonal Rabbit Anti-Human Alpha-1-Fetoprotein // 0.05 - 3 L
A0011 // Polyclonal Rabbit Anti-Human Orosomucoid // 0.05 - 3 L
A0012 // Polyclonal Rabbit Anti-Human Alpha-1-Antitrypsin // 0.05 - 3 L
A0021 // Polyclonal Rabbit Anti-Human Gc-Globulin // 0.05 - 3 L
A0022 // Polyclonal Rabbit Anti-Human Alpha-1-Antichymotrypsin // 0.05 - 3 L
A0024 // Polyclonal Rabbit Anti-Human Tau // 0.05 - 3 L
A0030 // Polyclonal Rabbit Anti-Human Haptoglobin // 0.05 - 3 L
A0031 // Polyclonal Rabbit Anti-Human Ceruloplasmin // 0.05 - 3 L
A0033 // Polyclonal Rabbit Anti-Human Alpha-2-Macroglobulin // 0.05 - 3 L
A0040 // Polyclonal Rabbit Anti-Human Retinol-Binding-Protein (RBP) // 0.05 - 3 L
A0061 // Polyclonal Rabbit Anti-Human Transferrin // 0.05 - 3 L
A0062 // Polyclonal Rabbit Anti-Human C3c Complement // 0.05 - 3 L
A0063 // Polyclonal Rabbit Anti-Human C3d Complement // 0.05 - 3 L
A0065 // Polyclonal Rabbit Anti-Human C4c Complement // 0.05 - 3 L
A0072 // Polyclonal Rabbit Anti-Human Beta-2-Microglobulin // 0.05 - 3 L
A0077 // Polyclonal Rabbit Anti-Human Apolipoprotein E // 0.05 - 3 L
A0080 // Polyclonal Rabbit Anti-Human Fibrinogen // 0.05 - 3 L
A0082 // Polyclonal Rabbit Anti-Human Von Willebrand Factor // 0.05 - 3 L
A0092 // Polyclonal Rabbit Anti-Human IgA, (Specific for Alpha-Chains) // 0.05 - 3 L
A0093 // Polyclonal Rabbit Anti-Human IgD, (Specific for Delta-Chains) // 0.05 - 3 L
A0094 // Polyclonal Rabbit Anti-Human IgE, (Specific for Epsilon-Chains) // 0.05 - 3 L
A0098 // Polyclonal Rabbit Anti-Human Progesterone Receptor // 0.05 - 3 L
A0099 // Polyclonal Rabbit Anti-Human Lysozyme // 0.05 - 3 L
A0100 // Polyclonal Rabbit Anti-Human Kappa Free Light Chains // 0.05 - 3 L
A0101 // Polyclonal Rabbit Anti-Human Lambda Free Light Chains // 0.05 - 3 L
A0115 // Polyclonal Rabbit Anti-Human Carcinoembryonic Antigen (CEA) // 0.05 - 3 L
A0118 // Polyclonal Rabbit Anti-Human Hemoglobin // 0.05 - 3 L
A0133 // Polyclonal Rabbit Anti-Human Ferritin // 0.05 - 3 L
A0136 // Polyclonal Rabbit Anti-Human C1q Complement // 0.05 - 3 L
A0137 // Polyclonal Rabbit Anti-Human Placental Lactogen (hPL) // 0.05 - 3 L
A0146 // Polyclonal Rabbit Anti-Human Geloslin // 0.05 - 3 L
A0186 // Polyclonal Rabbit Anti-Human Lactoferrin // 0.05 - 3 L
A0190 // Polyclonal Rabbit Anti-Human Polyclonal Rabbit anti Human IgA, IgG, IgM // 0.05 - 3 L
A0191 // Polyclonal Rabbit Anti-Human Kappa Light Chains // 20-500 mL

Date of issue: 07/24/2019
### Section 1. Identification

<table>
<thead>
<tr>
<th>Catalog Number</th>
<th>Description</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>A0192</td>
<td>Polyclonal Rabbit Anti-Human Kappa Light Chains</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0193</td>
<td>Polyclonal Rabbit Anti-Human Lambda Light Chains</td>
<td>20-30.000 mL</td>
</tr>
<tr>
<td>A0194</td>
<td>Polyclonal Rabbit Anti-Human Lambda Light Chains</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0206</td>
<td>Polyclonal Rabbit Anti-Human Serum</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0224</td>
<td>Polyclonal Rabbit Anti-Human Urine, Microproteins</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0225</td>
<td>Polyclonal Rabbit Anti-Human Thrombocyte</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0230</td>
<td>Polyclonal Rabbit Anti-Human Pregnancy-Associated Plasma Protein A (PAPP-A)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0231</td>
<td>Polyclonal Rabbit Anti-Human Human Chorionic Gonadotropin (hCG)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0245</td>
<td>Polyclonal Rabbit Anti-Human Fibronectin</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0251</td>
<td>Polyclonal Rabbit Anti-Human Thyroglobulin</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0253</td>
<td>Polyclonal Rabbit Anti-Human C1-Inactivator</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0262</td>
<td>Polyclonal Rabbit Anti-Human IgA, Specific for Alpha-Chains), ELISA pure</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0257</td>
<td>Polyclonal Rabbit Anti-Human Urine Protein 1</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0296</td>
<td>Polyclonal Rabbit Anti-Human Antithrombin III</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0301</td>
<td>Polyclonal Rabbit Anti-Human Inter-Alpha-Trypsin inhibitor</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0302</td>
<td>Polyclonal Rabbit Anti-Human P-Component</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0370</td>
<td>Polyclonal Rabbit Anti-Human Protein C</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0373</td>
<td>Polyclonal Rabbit Anti-Human Factor X</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0384</td>
<td>Polyclonal Rabbit Anti-Human Protein S</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0398</td>
<td>Polyclonal Rabbit Anti-Human Myeloperoxidase</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0408</td>
<td>Polyclonal Rabbit Anti-Human IgA, F(ab')2-fragmented (Specific for Alpha-Chains)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0423</td>
<td>Polyclonal Rabbit Anti-Human IgG, (Specific for Gamma-Chains), ELISA pure</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0424</td>
<td>Polyclonal Rabbit Anti-Human IgG, (Specific for Gamma-Chains)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0425</td>
<td>Polyclonal Rabbit Anti-Human IgM, (Specific for Mu-Chains), ELISA pure</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0426</td>
<td>Polyclonal Rabbit Anti-Human IgM, (Specific for Mu-Chains)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0451</td>
<td>Polyclonal Rabbit Anti-Human Cystatin C</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0452</td>
<td>Polyclonal Rabbit Anti-Human CD3</td>
<td>0.2 mL, 1mL</td>
</tr>
<tr>
<td>A0485</td>
<td>Polyclonal Rabbit Anti-Human c-erbB-2 Oncoprotein</td>
<td>0.2 mL</td>
</tr>
<tr>
<td>A0562</td>
<td>Polyclonal Rabbit Anti-Human Prostate Specific Antigen (PSA)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0564</td>
<td>Polyclonal Guinea Pig Anti-Insulin</td>
<td>1 mL</td>
</tr>
<tr>
<td>A0566</td>
<td>Polyclonal Rabbit Anti-Human Somatostatin</td>
<td>1mL</td>
</tr>
<tr>
<td>A0568</td>
<td>Polyclonal Rabbit Anti-Human Gastrin</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0569</td>
<td>Polyclonal Rabbit Anti-Human Prolactin</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0570</td>
<td>Polyclonal Rabbit Anti-Human Growth Hormone</td>
<td>1 mL</td>
</tr>
<tr>
<td>A0576</td>
<td>Polyclonal Rabbit Anti-Human Calcitonin</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A0623</td>
<td>Polyclonal Rabbit Anti-Human Myelin Basic Protein</td>
<td>1 mL</td>
</tr>
<tr>
<td>A4502</td>
<td>Polyclonal Rabbit Anti-Human CD117, c-kit</td>
<td>0.2 mL</td>
</tr>
<tr>
<td>A5109</td>
<td>Polyclonal Rabbit Anti-Human S100A1</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A5110</td>
<td>Polyclonal Rabbit Anti-Human S100B</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A5113</td>
<td>Polyclonal Rabbit Anti-Human S100A2</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>A5114</td>
<td>Polyclonal Rabbit Anti-Human CD117, c-kit</td>
<td>1 mL</td>
</tr>
<tr>
<td>A5115</td>
<td>Polyclonal Rabbit Anti-Human S100A6</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>B0114</td>
<td>Polyclonal Rabbit Anti-Herpes Simplex Virus Type 1</td>
<td>2 mL, 20-1.000 mL</td>
</tr>
<tr>
<td>B0357</td>
<td>Polyclonal Rabbit Anti-Escherichia Coli</td>
<td>20-200 mL</td>
</tr>
<tr>
<td>B0471</td>
<td>Polyclonal Rabbit Anti-Helicobacter Pylori</td>
<td>0.2 mL, 1-1200 mL</td>
</tr>
<tr>
<td>B0586</td>
<td>Polyclonal Rabbit Anti-Hepatitis B Virus Core Antigen</td>
<td>0.2 mL, 1 mL</td>
</tr>
<tr>
<td>O9127</td>
<td>Polyclonal Rabbit Anti-Human Lambda Free Light Chains</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>OA016</td>
<td>Polyclonal Rabbit Anti-Human kappa Free Light Chains</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>OA026</td>
<td>Polyclonal Rabbit Anti-Human Serum Amyloid A (SAA)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>OA044</td>
<td>Polyclonal Rabbit Anti-Human Myoglobin</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>OA500</td>
<td>Polyclonal Rabbit Anti-Human Albumin (Microalbumin) (RTU)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>OA521</td>
<td>Polyclonal Rabbit Anti-Human Apolipoprotein A-1 (RTU)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>OA522</td>
<td>Polyclonal Rabbit Anti-Human Apolipoprotein B (RTU)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>OA529</td>
<td>Polyclonal Rabbit Anti-Human Retinol-Binding-Protein (RBP) (RTU)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>OA541/Polyclonal Rabbit Anti-Human C-Reactive Protein, Slow-Reacting Antibody</td>
<td>0.05 - 3 L</td>
<td></td>
</tr>
<tr>
<td>Q0023</td>
<td>Polyclonal Rabbit Anti-Human Lipoprotein (a)</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>Q0102</td>
<td>Polyclonal Rabbit Anti-Human Alpha-2-Macroglobulin</td>
<td>0.05 - 3 L</td>
</tr>
<tr>
<td>Q0121</td>
<td>Polyclonal Rabbit Anti-Human Ceruloplasmin</td>
<td>0.05 - 3 L</td>
</tr>
</tbody>
</table>

**Date of issue:** 07/24/2019
Section 1. Identification

1.3 Details of the supplier of the safety data sheet
Supplier/Manufacturer : Dako North America, Inc.
6392 Via Real
Carpinteria, California 93013
United States
Tel: (805) 566-6655
www.Agilent.com

E-mail address of person responsible for this SDS : SDS@Agilent.com

1.4 Emergency telephone number
In case of emergency : CHEMTREC®: 1-800-424-9300

Section 2. Hazards identification

2.1 Classification of the substance or mixture
OSHA/HCS status : While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

Classification of the substance or mixture
Not classified.

Ingredients of unknown toxicity : Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: 1 - 10%

2.2 GHS label elements
Section 2. Hazards identification

<table>
<thead>
<tr>
<th>Signal word</th>
<th>No signal word.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hazard statements</td>
<td>No known significant effects or critical hazards.</td>
</tr>
</tbody>
</table>

Precautionary statements

| Prevention | Not applicable. |
| Response | Not applicable. |
| Storage | Not applicable. |
| Disposal | Not applicable. |

2.3 Other hazards

Hazard statements not otherwise classified: None known.

Section 3. Composition/information on ingredients

Substance/mixture: Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section. Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

4.1 Description of necessary first aid measures

Eye contact: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.

Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Skin contact: Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.

Ingestion: Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

4.2 Most important symptoms/effects, acute and delayed

Potential acute health effects

| Eye contact | No known significant effects or critical hazards. |
| Inhalation | No known significant effects or critical hazards. |
| Skin contact | No known significant effects or critical hazards. |
| Ingestion | No known significant effects or critical hazards. |

Over-exposure signs/symptoms

| Eye contact | No specific data. |
| Inhalation | No specific data. |
| Skin contact | No specific data. |
| Ingestion | No specific data. |

4.3 Indication of immediate medical attention and special treatment needed, if necessary

Date of issue: 07/24/2019
Section 4. First aid measures

Notes to physician : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Specific treatments : No specific treatment.

Protection of first-aiders : No action shall be taken involving any personal risk or without suitable training.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

5.1 Extinguishing media

Suitable extinguishing media : Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards arising from the chemical : In a fire or if heated, a pressure increase will occur and the container may burst.

Hazardous thermal decomposition products : Decomposition products may include the following materials:
- carbon dioxide
- carbon monoxide
- nitrogen oxides
- phosphorus oxides

5.3 Advice for firefighters

Special protective actions for fire-fighters : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

For emergency responders : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and materials for containment and cleaning up

Methods for cleaning up : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Section 7. Handling and storage

7.1 Precautions for safe handling

Protective measures
- Put on appropriate personal protective equipment (see Section 8).

Advice on general occupational hygiene
- Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities
- Specific storage conditions: Please consult the label.
- Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

Recommendations
- Industrial applications, Professional applications.

Industrial sector specific solutions
- Not applicable.

Section 8. Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

<table>
<thead>
<tr>
<th>Ingredient name</th>
<th>Exposure limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>None.</td>
<td>None.</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Appropriate engineering controls
- Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Environmental exposure controls
- Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures
- Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection
- Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection
- Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Date of issue: 07/24/2019
Section 8. Exposure controls/personal protection

**Body protection**: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Other skin protection**: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection**: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties

**9.1 Information on basic physical and chemical properties**

**Appearance**
- **Physical state**: Liquid.
- **Color**: Not available.
- **Odor**: Not available.
- **Odor threshold**: Not available.
- **pH**: 6.5 to 8.5
- **Melting point**: Not available.
- **Boiling point**: Not available.
- **Flash point**: Not available.
- **Evaporation rate**: Not available.
- **Flammability (solid, gas)**: Not applicable.
- **Lower and upper explosive (flammable) limits**: Not available.
- **Vapor pressure**: Not available.
- **Vapor density**: Not available.
- **Relative density**: Not available.
- **Solubility**: Soluble in the following materials: cold water and hot water.
- **Partition coefficient: n-octanol/water**: Not available.
- **Auto-ignition temperature**: Not available.
- **Decomposition temperature**: Not available.
- **Viscosity**: Not available.

Section 10. Stability and reactivity

**10.1 Reactivity**: No specific test data related to reactivity available for this product or its ingredients.

**10.2 Chemical stability**: The product is stable.

**10.3 Possibility of hazardous reactions**: Under normal conditions of storage and use, hazardous reactions will not occur.

**10.4 Conditions to avoid**: No specific data.

**10.5 Incompatible materials**: May react or be incompatible with oxidizing materials.

**Date of issue :** 07/24/2019
Section 10. Stability and reactivity

10.6 Hazardous decomposition products
Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

11.1 Information on toxicological effects

Acute toxicity
Not available.

Irritation/Corrosion
Not available.

Sensitization
Not available.

Mutagenicity
Conclusion/Summary : Not available.

Carcinogenicity
Conclusion/Summary : Not available.

Reproductive toxicity
Conclusion/Summary : Not available.

Teratogenicity
Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)
Not available.

Specific target organ toxicity (repeated exposure)
Not available.

Aspiration hazard
Not available.

Information on the likely routes of exposure
Not available.

Potential acute health effects

Eye contact : No known significant effects or critical hazards.
Inhalation : No known significant effects or critical hazards.
Skin contact : No known significant effects or critical hazards.
Ingestion : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.
Inhalation : No specific data.
Skin contact : No specific data.
Ingestion : No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure
Potential immediate effects : Not available.
Section 11. Toxicological information

Potential delayed effects : Not available.
Long term exposure
Potential immediate effects : Not available.
Potential delayed effects : Not available.

Potential chronic health effects
General : No known significant effects or critical hazards.
Carcinogenicity : No known significant effects or critical hazards.
Mutagenicity : No known significant effects or critical hazards.
Teratogenicity : No known significant effects or critical hazards.
Developmental effects : No known significant effects or critical hazards.
Fertility effects : No known significant effects or critical hazards.

Numerical measures of toxicity
Acute toxicity estimates
N/A

Section 12. Ecological information

12.1 Toxicity
Not available.

12.2 Persistence and degradability
Not available.

12.3 Bioaccumulative potential
Not available.

12.4 Mobility in soil
Soil/water partition coefficient (K<sub>oc</sub>) : Not available.

12.5 Other adverse effects : No known significant effects or critical hazards.

Section 13. Disposal considerations

13.1 Waste treatment methods
Disposal methods : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Date of issue : 07/24/2019
Section 13. Disposal considerations

Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements.

The information presented below only applies to the material as supplied. The identification based on characteristic(s) or listing may not apply if the material has been used or otherwise contaminated. It is the responsibility of the waste generator to determine the toxicity and physical properties of the material generated to determine the proper waste identification and disposal methods in compliance with applicable regulations.

Refer to Section 7: HANDLING AND STORAGE and Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION for additional handling information and protection of employees.

Section 14. Transport information

DOT / TDG / Mexico / IMDG / IATA: Not regulated.

Special precautions for user: Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according to Annex II of MARPOL and the IBC Code: Not available.

Section 15. Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

U.S. Federal regulations: TSCA 8(a) CDR Exempt/Partial exemption: Not determined

Clean Air Act  Section 112 (b) Hazardous Air Pollutants (HAPs): Not listed
Clean Air Act Section 602 Class I Substances: Not listed
Clean Air Act Section 602 Class II Substances: Not listed
DEA List I Chemicals (Precursor Chemicals): Not listed
DEA List II Chemicals (Essential Chemicals): Not listed
SARA 302/304
Composition/information on ingredients

<table>
<thead>
<tr>
<th>Name</th>
<th>%</th>
<th>EHS</th>
<th>SARA 302 TPQ (lbs)</th>
<th>SARA 302 RQ (gallons)</th>
<th>SARA 304 RQ (lbs)</th>
<th>SARA 304 RQ (gallons)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium azide</td>
<td>&lt;0.1</td>
<td>Yes.</td>
<td>500</td>
<td>-</td>
<td>1000</td>
<td>-</td>
</tr>
</tbody>
</table>

SARA 304 RQ: 1025641 lbs / 465641 kg

SARA 311/312
Classification: Not applicable.

Composition/information on ingredients
No products were found.

Date of issue: 07/24/2019
Section 15. Regulatory information

State regulations

Massachusetts: None of the components are listed.
New York: None of the components are listed.
New Jersey: None of the components are listed.
Pennsylvania: None of the components are listed.

California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Australia: Not determined.
Canada: Not determined.
China: All components are listed or exempted.
Europe: All components are listed or exempted.
Japan: Japan inventory (ENCS): Not determined. Japan inventory (ISHL): All components are listed or exempted.
New Zealand: Not determined.
Philippines: Not determined.
Republic of Korea: Not determined.
Taiwan: All components are listed or exempted.
Thailand: Not determined.
Turkey: Not determined.
United States: All components are listed or exempted.
Viet Nam: Not determined.

Section 16. Other information

History

Date of issue: 07/24/2019
Date of previous issue: 10/26/2017
Version: 4
Section 16. Other information

**Key to abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATE</td>
<td>Acute Toxicity Estimate</td>
</tr>
<tr>
<td>BCF</td>
<td>Bioconcentration Factor</td>
</tr>
<tr>
<td>GHS</td>
<td>Globally Harmonized System of Classification and Labelling of Chemicals</td>
</tr>
<tr>
<td>IATA</td>
<td>International Air Transport Association</td>
</tr>
<tr>
<td>IBC</td>
<td>Intermediate Bulk Container</td>
</tr>
<tr>
<td>IMDG</td>
<td>International Maritime Dangerous Goods</td>
</tr>
<tr>
<td>LogPow</td>
<td>Logarithm of the octanol/water partition coefficient</td>
</tr>
<tr>
<td>N/A</td>
<td>Not available</td>
</tr>
<tr>
<td>UN</td>
<td>United Nations</td>
</tr>
</tbody>
</table>

**Procedure used to derive the classification**

<table>
<thead>
<tr>
<th>Classification</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not classified.</td>
<td></td>
</tr>
</tbody>
</table>

* Indicates information that has changed from previously issued version.

**Notice to reader**

Disclaimer: The information contained in this document is based on Dako state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.